1. Home
  2. TC vs FEMY Comparison

TC vs FEMY Comparison

Compare TC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TuanChe Limited

TC

TuanChe Limited

N/A

Current Price

$7.57

Market Cap

29.0M

ML Signal

N/A

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.62

Market Cap

34.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TC
FEMY
Founded
2010
2004
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.0M
34.3M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
TC
FEMY
Price
$7.57
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.83
AVG Volume (30 Days)
14.4K
1.5M
Earning Date
12-16-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,115,721.00
$2,061,502.00
Revenue This Year
N/A
$64.02
Revenue Next Year
N/A
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.53
52 Week Low
$6.50
$0.31
52 Week High
$39.00
$1.80

Technical Indicators

Market Signals
Indicator
TC
FEMY
Relative Strength Index (RSI) 25.13 39.60
Support Level $6.70 $0.58
Resistance Level $7.94 $0.66
Average True Range (ATR) 1.10 0.07
MACD -0.05 -0.02
Stochastic Oscillator 14.67 23.93

Price Performance

Historical Comparison
TC
FEMY

About TC TuanChe Limited

Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: